麗珠醫藥(01513.HK)擬2112.3萬元出售麗珠試劑9.5%股權予公司高管持股基金
格隆匯11月8日丨麗珠醫藥(01513.HK)公佈,於2019年11月8日,公司與麗英訂立股權轉讓協議,據此,公司同意出售而麗英同意收購麗珠試劑9.50%股權,對價為人民幣2112.3萬元。於出售事項完成後,該公司將持有麗珠試劑41.50%股權。
麗珠試劑為一家於1989年1月26日在中國成立的股份有限公司,其主要從事體外診斷試劑的生產。麗珠試劑截至2017年12月31日及2018年12月31日止兩個財政年度淨利潤分別為6629.5萬元及6473.8萬元。
麗英為一家於2019年在中國成立的有限合夥企業,其主要從事股權投資、投資管理、投資策劃及投資諮詢。於本公告日期,公司執行董事唐陽剛先生為麗英的普通合夥人,有權單獨決定麗英的一切事宜,且擁有麗英的19.9234%權益。麗英剩餘的80.0766%權益由其他人士擁有。其他合夥人包括公司的董事及高級管理人員,以及公司及控股附屬公司的核心管理人員。
董事認為,出售事項可使該集團核心管理人員與麗珠試劑的業務發展形成直接利益捆綁關係,既能夠充分調動該集團經營管理層及核心員工的積極性,又能夠穩定和吸引核心人才,從而有效促進麗珠試劑經營業務發展,推進該集團未來發展戰略和整體經營目標的實現。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.